Shield Therapeutics (LON:STX) Reaches New 52-Week High – Should You Buy?

Shield Therapeutics plc (LON:STX)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as GBX 12.50 and last traded at GBX 11.50, with a volume of 2757713 shares changing hands. The stock had previously closed at GBX 11.20.

Analyst Ratings Changes

Separately, Peel Hunt reaffirmed a “buy” rating and issued a GBX 15 price target on shares of Shield Therapeutics in a report on Friday, November 7th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of GBX 15.

Shield Therapeutics Price Performance

The firm’s fifty day simple moving average is GBX 8.39 and its 200-day simple moving average is GBX 6.34. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The firm has a market capitalization of £122.11 million, a PE ratio of -5.75 and a beta of 1.42.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.